Health TidingsEBGLYSS Shows Rapid Improvements in Hand and Foot Atopic Dermatitis EBGLYSS Shows Rapid Improvements in Hand and Foot Atopic Dermatitis Read Post »
Health TidingsIopofosine I 131 Shows 87.5% Response Rate in Waldenström Macroglobulinemi... Iopofosine I 131 Shows 87.5% Response Rate in Waldenström Macroglobulinemi... Read Post »
Health TidingsLilly’s EloraTZP Delivers Up to 23.3% Weight Loss and 2.9% A1C Reduction ... Lilly’s EloraTZP Delivers Up to 23.3% Weight Loss and 2.9% A1C Reduction ... Read Post »
Health TidingsTrappsol Cyclo Shows Benefit in NPC Trial, Misses Statistical Significance Trappsol Cyclo Shows Benefit in NPC Trial, Misses Statistical Significance Read Post »
Clinical TrialsVanda’s Tasimelteon Advances Sleep Onset in Phase III Delayed Sleep-Wake ... Vanda’s Tasimelteon Advances Sleep Onset in Phase III Delayed Sleep-Wake ... Read Post »
Clinical TrialsAbbVie’s ABBV-295 Shows Up to 9.8% Weight Reduction in Phase 1 Study AbbVie’s ABBV-295 Shows Up to 9.8% Weight Reduction in Phase 1 Study Read Post »
Clinical TrialsZumilokibart Phase 2 Results Show EASI-75 Benefit in Atopic Dermatitis Zumilokibart Phase 2 Results Show EASI-75 Benefit in Atopic Dermatitis Read Post »
Health TidingsTelix BiPASS Program Gets FDA Fast Track for Prostate Cancer Imaging Telix BiPASS Program Gets FDA Fast Track for Prostate Cancer Imaging Read Post »
Health TidingsFDA Accepts Roche’s Fenebrutinib NDA Under Priority Review for Relapsing ... FDA Accepts Roche’s Fenebrutinib NDA Under Priority Review for Relapsing ... Read Post »
Health TidingsAlmirall’s New Lebrikizumab and Tildrakizumab Data Highlight Long-Term Ou... Almirall’s New Lebrikizumab and Tildrakizumab Data Highlight Long-Term Ou... Read Post »
Clinical TrialsGalderma’s Nemluvio Shows Sustained Atopic Dermatitis Benefits in 3-Year ... Galderma’s Nemluvio Shows Sustained Atopic Dermatitis Benefits in 3-Year ... Read Post »
Clinical TrialsOral Safiglipron Demonstrates Glycemic Efficacy in Phase 3 Trial of Early T... Oral Safiglipron Demonstrates Glycemic Efficacy in Phase 3 Trial of Early T... Read Post »
Health TidingsZepbound vs Wegovy HD: Tirzepatide Shows Greater Weight Loss Zepbound vs Wegovy HD: Tirzepatide Shows Greater Weight Loss Read Post »
Health TidingsZeleciment Basivarsen Shows Sustained Functional Improvement in Myotonic Dy... Zeleciment Basivarsen Shows Sustained Functional Improvement in Myotonic Dy... Read Post »
Clinical TrialsPetrelintide Achieves Double-Digit Weight Loss with Placebo-Like GI Profile... Petrelintide Achieves Double-Digit Weight Loss with Placebo-Like GI Profile... Read Post »
Clinical TrialsRetatrutide Shows Up to 20.8% Weight Loss and A1C Reduction in TRIUMPH-2 Tr... Retatrutide Shows Up to 20.8% Weight Loss and A1C Reduction in TRIUMPH-2 Tr... Read Post »
Health Tidings Medical DevicesGammaTile Shows Superior Tumor Control and Overall Survival in Phase 3 ROAD... GammaTile Shows Superior Tumor Control and Overall Survival in Phase 3 ROAD... Read Post »
Health TidingsInvivyd VYD2311 Shows Positive Phase 3 LIBERTY Results in COVID-19 Invivyd VYD2311 Shows Positive Phase 3 LIBERTY Results in COVID-19 Read Post »
Health TidingsIfezuntirgene Inilparvovec Shows 48-Month Data in Huntington’s Disease Ifezuntirgene Inilparvovec Shows 48-Month Data in Huntington’s Disease Read Post »
Clinical TrialsDescartes-08 Retreatment Sustains Clinical Improvements in Generalized Myas... Descartes-08 Retreatment Sustains Clinical Improvements in Generalized Myas... Read Post »
Clinical TrialsTectonic Reports Favorable Phase 1a Results for TX2100 in Hemorrhagic Telan... Tectonic Reports Favorable Phase 1a Results for TX2100 in Hemorrhagic Telan... Read Post »
Health TidingsHUTCHMED, AstraZeneca Submit US NDA for ORPATHYS + TAGRISSO HUTCHMED, AstraZeneca Submit US NDA for ORPATHYS + TAGRISSO Read Post »
Clinical TrialsFoundayo 17.2 mg Shows Greater Weight Loss and A1C Reduction Than Oral Sema... Foundayo 17.2 mg Shows Greater Weight Loss and A1C Reduction Than Oral Sema... Read Post »
Health Tidings Mergers & AcquisitionsAstraZeneca Invests $2 Billion in Summit to Advance Ivonescimab-ADC Combina... AstraZeneca Invests $2 Billion in Summit to Advance Ivonescimab-ADC Combina... Read Post »
New Drug ApprovalFDA Approves Gazyva (Obinutuzumab) for Idiopathic Nephrotic Syndrome in Pat... FDA Approves Gazyva (Obinutuzumab) for Idiopathic Nephrotic Syndrome in Pat... Read Post »
Health Tidings Mergers & AcquisitionsNovo Secures Global Rights to Hengrui’s Once-Weekly Oral GLP-1/GIP Agonis... Novo Secures Global Rights to Hengrui’s Once-Weekly Oral GLP-1/GIP Agonis... Read Post »
GenericsTeva’s DEGEVMA Receives U.S. FDA Approval as Biosimilar to Xgeva Teva’s DEGEVMA Receives U.S. FDA Approval as Biosimilar to Xgeva Read Post »
Clinical TrialsMirum’ Brelovitug Meets Phase 3 Endpoint in Chronic Hepatitis Delta Mirum’ Brelovitug Meets Phase 3 Endpoint in Chronic Hepatitis Delta Read Post »
Health TidingsIfinatamab Deruxtecan BLA Withdrawn for ES-SCLC Ifinatamab Deruxtecan BLA Withdrawn for ES-SCLC Read Post »
Health Tidings Mergers & AcquisitionsMerck and SciBrunch Sign $2.13 Billion Deal for KRAS G12D Inhibitor SPR2015 Merck and SciBrunch Sign $2.13 Billion Deal for KRAS G12D Inhibitor SPR2015 Read Post »
New Drug ApprovalFDA Approves EMCITATE® (tiratricol), First Treatment for MCT8 Deficiency FDA Approves EMCITATE® (tiratricol), First Treatment for MCT8 Deficiency Read Post »
Clinical TrialsAscletis’ ASC50 Shows Sustained PASI Reduction, Supporting Longer-Duratio... Ascletis’ ASC50 Shows Sustained PASI Reduction, Supporting Longer-Duratio... Read Post »
Health TidingsTTX-MC138 Shows Sustained Disease Control in Phase 1a Trial TTX-MC138 Shows Sustained Disease Control in Phase 1a Trial Read Post »
Clinical TrialsDenifanstat Shows Sustained Efficacy Through 52 Weeks in Phase 3 Acne Exten... Denifanstat Shows Sustained Efficacy Through 52 Weeks in Phase 3 Acne Exten... Read Post »
Clinical TrialsZenkuda Meets DAYBREAK Endpoint With Sustained Six-Month Dosing in Wet AMD Zenkuda Meets DAYBREAK Endpoint With Sustained Six-Month Dosing in Wet AMD Read Post »
Health TidingsFDA Grants Priority Review for Elinzanetant in Breast Cancer VMS FDA Grants Priority Review for Elinzanetant in Breast Cancer VMS Read Post »
Clinical TrialsEvorpacept Shows Stronger Responses in HER2+ Gastric Cancer Evorpacept Shows Stronger Responses in HER2+ Gastric Cancer Read Post »
New Drug ApprovalFDA Approves WELIREG Plus LENVIMA for Advanced ccRCC FDA Approves WELIREG Plus LENVIMA for Advanced ccRCC Read Post »
GenericsLupin Secures U.S. FDA Tentative Approval for Apixaban Oral Suspension Lupin Secures U.S. FDA Tentative Approval for Apixaban Oral Suspension Read Post »
Health TidingsAkeso Launches Global Phase III Trial of Cadonilimab in First-Line HER2-Neg... Akeso Launches Global Phase III Trial of Cadonilimab in First-Line HER2-Neg... Read Post »
Health TidingsTipelukast Improves HDL-C and HDL-P in Phase 2 Trial, While Key Endpoints F... Tipelukast Improves HDL-C and HDL-P in Phase 2 Trial, While Key Endpoints F... Read Post »
Clinical TrialsVitamin K2 and D3 Slow Coronary Artery Calcification Progression in DANCODE... Vitamin K2 and D3 Slow Coronary Artery Calcification Progression in DANCODE... Read Post »
Clinical TrialsITM-11 Re-treatment Shows Promising Real-World Survival in SwissNet Analysi... ITM-11 Re-treatment Shows Promising Real-World Survival in SwissNet Analysi... Read Post »
New Drug ApprovalAbbVie’s Jumvo (Tavapadon) Receives FDA Approval for Parkinson’s Diseas... AbbVie’s Jumvo (Tavapadon) Receives FDA Approval for Parkinson’s Diseas... Read Post »
Health TidingsInnovent and Takeda Expand Phase 3 IBI363 Program to Non-Squamous NSCLC Innovent and Takeda Expand Phase 3 IBI363 Program to Non-Squamous NSCLC Read Post »
New Drug ApprovalFDA Approves Atebrioz (zilurgisertib) for FOP Treatment FDA Approves Atebrioz (zilurgisertib) for FOP Treatment Read Post »
New Drug ApprovalFDA Expands Olumiant Approval to Adolescents with Severe Alopecia Areata FDA Expands Olumiant Approval to Adolescents with Severe Alopecia Areata Read Post »
Health TidingsZENBEXUS Shows Deeper Responses in Relapsed Multiple Myeloma ZENBEXUS Shows Deeper Responses in Relapsed Multiple Myeloma Read Post »
Health TidingsCARVYKTI Shows 5-Year Disease Control in Multiple Myeloma CARVYKTI Shows 5-Year Disease Control in Multiple Myeloma Read Post »
Health TidingsClywedog’s balomenib Shows Sustained HbA1c Reduction in Type 2 Diabetes Clywedog’s balomenib Shows Sustained HbA1c Reduction in Type 2 Diabetes Read Post »
